PRIME Awards 2026 | Insights from three years of GP nominations
Innovation matters. But when Australian GPs recognise a pharmaceutical company for excellence, their reasons go well beyond the medicines it develops.
What makes a pharmaceutical company stand out to Australian GPs? Breakthrough medicines, quality medical education, knowledgeable representatives or meaningful support for patients?
An analysis of nominations for the PRIME Awards’ GPs’ Choice: Pharma Company of the Year, spanning 2024 to 2026, reveals what doctors genuinely value.
The message is consistent: GPs recognise companies that combine clinical innovation with practical support, credible education and a genuine commitment to better patient outcomes.
Just as importantly, everyday interactions matter. A knowledgeable representative, useful educational resource or timely response to a clinical question can leave a lasting impression.
1. Innovation earns attention. Patient outcomes earn respect.
Developing effective medicines remains a powerful reason for GPs to recognise pharmaceutical companies. Across the three years, doctors highlighted advances in chronic disease management, vaccination programs and investment in research.
In 2026, particular attention was given to diabetes, obesity and metabolic health, alongside cardiovascular and other chronic conditions.
One GP recognised a company for its:
“Great innovative products which have helped a lot of patients”
Another highlighted first-in-class medicines and strong clinical research.
The distinction is important. GPs are not simply recognising innovation for its own sake. They want evidence that new treatments make a meaningful difference to their patients.
The industry takeaway: Innovation gets noticed. Demonstrating its real-world clinical value earns recognition.
2. Education is one of pharma’s most valued contributions.
High-quality medical education consistently emerges as a key reason for GP recognition.
Doctors praised companies for relevant educational events, practical clinical resources, knowledgeable speakers and access to emerging treatment information. In 2024, one GP highlighted:
“Excellent educational activities, minimal product selling”
In 2026, respondents continued to recognise educational programs and clinical support, particularly in rapidly evolving therapeutic areas.
What stands out is the distinction between education and promotion. GPs value information that helps them make better clinical decisions, not simply encourages prescribing.
The industry takeaway: Education builds credibility when it is evidence-based, clinically relevant and designed around doctors’ needs rather than promotional priorities.
3. The pharmaceutical representative still matters.
Despite the growth of digital information, the quality of pharmaceutical representatives remains an important factor in GP nominations. Doctors recognised representatives who were knowledgeable, accessible, respectful of their time and responsive to requests.
In 2025, one GP praised a representative who:
“doesn’t hassle – not overbearing”
In 2026, another recognised representatives who were frank about both the benefits and limitations of their products.
The message is clear. GPs don’t necessarily want more interactions. They want better ones.
The industry takeaway: Quality beats frequency. Representatives who provide credible information and respect doctors’ time build stronger relationships.
4. Practical support makes a difference.
Beyond innovation and education, GPs recognised companies that made everyday clinical practice easier. Nominations highlighted product samples, reliable medicine supply, timely clinical information and assistance for patients facing barriers to treatment.
One GP in 2026 recognised a company for:
“Good patient support, Good educational support for GPs, Great response to clinical enquiries”
Another highlighted access to treatment samples for disadvantaged patients. For a busy GP, being able to resolve a prescribing question quickly or help a patient access treatment can be particularly valuable.
The industry takeaway: Practical support builds goodwill and trust by helping doctors deliver better patient care.
5. Trust and transparency are powerful differentiators.
How pharmaceutical companies conduct themselves matters as much as what they offer.
Doctors recognised companies for ethical behaviour, professionalism, reliability and honest communication. Several nominations specifically praised representatives who avoided aggressive sales tactics or provided balanced clinical information.
In 2024, one GP valued educational discussions without pressure to prescribe a particular product. By 2026, doctors were explicitly recognising openness about treatment benefits and limitations.
These responses suggest that trust is earned through consistent behaviour, not individual campaigns.
The industry takeaway: Transparency and ethical engagement are more than compliance obligations. They are important drivers of reputation and trust.
6. A broader contribution to healthcare matters.
Some GPs also considered the wider contribution pharmaceutical companies make to healthcare and society. Nominations recognised vaccination programs, public health initiatives, charitable contributions and efforts to improve medicine access.
These responses suggest that purpose and broader healthcare impact can influence how doctors perceive a company beyond its individual products.
The industry takeaway: A genuine commitment to public health, equity and patient access strengthens a company’s standing with the medical profession.
What pharmaceutical companies can learn
Perhaps the most important insight is that GPs appear to recognise companies that make a genuine difference to their ability to deliver better care, rather than those that communicate their achievements most frequently.
Clinical innovation remains fundamental, but it is only part of the picture.
The nominations suggest that GPs also judge pharmaceutical companies on how effectively they translate innovation into everyday clinical practice, whether through better education, trusted representatives, responsive support or improved access to treatment.
For pharmaceutical companies, the opportunity is clear: invest in activities that deliver meaningful value to doctors and their patients, not simply greater visibility.
Recognising excellence through the PRIME Awards
The PRIME Awards celebrate excellence across Australia’s pharmaceutical and healthcare industries.
The GPs’ Choice: Pharma Company of the Year category offers a particularly valuable perspective, recognising companies through the experiences and opinions of Australian GPs.
The companies that stand out are not necessarily those that do the most. They are those whose contributions doctors find most meaningful.
The PRIME Awards 2026 will be held on Thursday 19 November at Sofitel Sydney Wentworth.
Learn more: https://www.primeawards.com.au/
Turn GP insights into stronger engagement
Understanding what GPs value is only the first step. AusDoc helps pharmaceutical companies connect with Australian doctors through trusted medical media, targeted communications and insights-led campaigns that deliver meaningful engagement.
Contact us to explore how AusDoc can help your brand build stronger relationships with Australian GPs.
References
Source: PRIME Awards, GPs’ Choice: Pharma Company of the Year nomination responses, 2024–2026.